XLV241206P151000
- 4.00
- 0.000.00%
The Health Care Select Sector SPDR® Fund Newsroom
S&P 500, Nasdaq, and Dow Hit Trading and Closing Records | Wall Street Today
Check Out What Whales Are Doing With ABBV
10 Health Care Stocks Whale Activity In Today's Session
Alector Downgraded to Underperform at BofA After Alzheimer's Trial Miss
Stock Of The Day: Where Will The Eli Lilly Rally End?
S&P and Nasdaq on Track for Third Record Close This Week | Live Stock
Insurance industry sudden incident! UnitedHealth insurance company CEO assassinated and died in New York, investor day event urgently canceled.
UnitedHealth CEO Brian Thompson was shot dead in Manhattan, New York. According to sources, the incident is believed to be a targeted attack. The UnitedHealth insurance company, which Thompson helmed, is the largest private health insurance company in the USA, with revenue exceeding $281 billion last year, accounting for over two-thirds of UnitedHealth Group's total revenue. On Wednesday, the US stock market UnitedHealth (UNH) stock price rose more than 2.9% in early trading but then gave back most of the gains.
UnitedHealth Group Issued 2025 Guidance Ahead Of Now Stopped Investor Conference
Decoding Eli Lilly's Options Activity: What's the Big Picture?
Sector Update: Health Care Stocks Steady Pre-Bell Wednesday
Incyte Gains Amid Takeover Speculation
'UnitedHealthcare CEO Fatally Shot In Midtown: Sources' - PIX11
Eli Lilly and Co announced the comparative trial results: Zepbound's weight-loss effect is better than Novo Nordisk's Wegovy.
eli lilly and co announced on Wednesday that in a comparative trial, its weight loss drug Zepbound had a greater weight loss effect than the competitor novo-nordisk a/s's similar drug Wegovy; eli lilly is still evaluating the trial results, the company stated that it plans to publish them in a peer-reviewed journal and present them at medical conferences next year.
Better than Wegovy! eli lilly and co's weight loss drug Zepbound averaged a 20% weight loss over 72 weeks, with a 2.5% pre-market surge.
Participants using Wegovy from novo-nordisk a/s only experienced a 14% reduction. This result presents eli lilly and co with an opportunity to surpass, especially with the obesity drug market expected to reach 130 billion USD by the end of this decade.
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Ahead of Powell Speech
Leading And Lagging Sectors For December 4, 2024
Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money'
US Morning News Call | Stock Index Futures Climb on Positive Earnings, Focus Shifts to Upcoming Speech by Powell
Eli Lilly Announced Topline Results From The SURMOUNT-5 Phase 3b Open-label Randomized Clinical Trial
UnitedHealth Group Introduces FY25 Guidance, Sees EPS $29.50-$30.00 Vs $29.92 Est.; Revenue $450B-$455B Vs $431.435B Est.